checkAd
    Startseite > Aktien > Ascendis Pharma > Nachrichten
    Ascendis Pharma Aktie
    143,18
     
    USD
    -1,14 %
    -1,65 USD
    Letzter Kurs 02:00:00 Nasdaq
    143,17
     
    USD
    1.000 STK
    Geldkurs 24.04.24
    143,35
     
    USD
    500 STK
    Briefkurs 24.04.24
    ISIN: US04351P1012 · WKN: A14M6X · SYM: ASND · Dänemark

    Neueste Nachrichten

    United Kingdom’s MHRA Approves YORVIPATH (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism
    24.04.24 · globenewswire · Ascendis Pharma
    Fokus Aktien mit extremen Handelsvolumen am Montag, den 01.04.2024
    01.04.24 · wO Chartvergleich · Consolidated Water
    Fokus Aktien mit extremen Handelsvolumen am Freitag, den 29.03.2024
    29.03.24 · wO Chartvergleich · Consolidated Water
    Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024
    04.03.24 · globenewswire · Ascendis Pharma
    Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results
    07.02.24 · globenewswire · Ascendis Pharma
    Ascendis Pharma to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
    07.02.24 · globenewswire · Ascendis Pharma
    Ascendis Pharma to Report Full Year 2023 Financial Results and Provide Business Update on February 7, 2024
    31.01.24 · globenewswire · Ascendis Pharma
    Ascendis Pharma Launches 2nd TransCon Product:  YORVIPATH Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism
    31.01.24 · globenewswire · Ascendis Pharma
    New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors
    29.01.24 · globenewswire · Ascendis Pharma
    Ascendis Pharma Introduces Vision 2030
    07.01.24 · globenewswire · Ascendis Pharma
    Ascendis Pharma to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
    28.12.23 · globenewswire · Ascendis Pharma
    Significant Health and Quality of Life Improvements Achieved in Children with Achondroplasia Treated for One Year with TransCon CNP (Navepegritide) at 100 µg/kg/week
    20.12.23 · globenewswire · Ascendis Pharma